[MARKET ANALYSIS] European equities coming under modest pressure, Roche hit as weight loss drug disappoints; US equity futures softer heading into NFP

European bourses (STOXX 600 U/C) are trading mixed, with the DAX 40 (+0.4%) outperforming, while the SMI (-0.9%) lags following losses in Roche (-3.1%).
Sectors are mixed, with Industrial Goods and Services (+0.8%) and Energy (+0.8%) sitting at the top of the pile. IMI (+3.1%) is benefiting from a decent set of FY earnings and the announcement of a share buyback programme of up to USD 500mln. Health Care (-0.8%) is coming under pressure this morning after a Roche-Zealand Pharma weight loss drug failed to meet industry expectations (Jefferies analyst states 13-15% weight loss was the bar). Petrelintide showed 10.7% weight loss after 42 weeks of treatment, which is much less than Eli Lilly's 20% weight loss for a similar drug.
Other key movers include Lufthansa (+2.7%), Infineon (-3.4%) and UMG (-4.7%). For the German airliner, the Co. posted FY revenue that missed estimates but guided 2026 adjusted EBIT and revenue clearly increasing from 2025 levels, resulting in the gains seen in the name. Within the Co.'s earnings, UMG announced that it is not the right time to move ahead with a US listing due to the current market uncertainty in its valuation. Finally, for Infineon, the Co. was downgraded to neutral from buy at UBS.
US equity futures (ES/NQ/RTY -0.3%) are trading modestly lower as the European session continues. Focusing on the broader ES, the index has managed to hold within the broader 6774-7010 range but could see positions unwind on a break lower if bond volatility continues to rise. History has shown that equities underperform in times of rising bond volatility.